| # | Country | Total Patents | |
|---|---|---|---|
| #1 | United States | 3 | |
| #2 | Australia | 2 | |
| #3 | Canada | 2 | |
| #4 | China | 2 | |
| #5 | EPO (European Patent Office) | 2 | |
| #6 | Republic of Korea | 2 | |
| #7 | Mexico | 2 | |
| #8 | WIPO (World Intellectual Property Organization) | 2 | |
| #9 | Hong Kong | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Biotechnology |
| # | Technology | |
|---|---|---|
| #1 | Peptides | |
| #2 | Medical preparations | |
| #3 | Therapeutic chemical compounds |
| # | Name | Total Patents |
|---|---|---|
| #1 | Ahonen Cory | 16 |
| #2 | Noelle Randolph | 16 |
| #3 | Kedl Ross | 6 |
| #4 | Kedl Ross M | 1 |
| #5 | Cory Ahonen | 1 |
| #6 | Noelle Randolph J | 1 |
| #7 | Randolph Noelle | 1 |
| #8 | Ahonen Cory L | 1 |
| #9 | Ross Kedl | 1 |
| Publication | Filing date | Title |
|---|---|---|
| WO2008157473A1 | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens | |
| AU2008246149A1 | Adjuvant combinations of NKT activator, CD40 agonist, and optional antigen, the use through inducing synergistic cellular immunity |